Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.65 |
| ▸ | MMP2 | P08253 | 9/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571626 | 1.00 | MMP9 (0.65) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| Hydrochloric Acid SCHEMBL14059215 | 0.99 | MMP9 (0.64) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL457772 | 0.92 | MMP9 (0.76) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL8001084 | 0.92 | MMP9 (0.76) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL10585071 | 0.92 | MMP9 (0.76) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL8322406 | 0.91 | MMP9 (0.71) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| Hydrochloric Acid SCHEMBL9087107 | 0.91 | MMP9 (0.74) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL77677 | 0.90 | MMP9 (0.67) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL2038720 | 0.90 | MMP9 (0.67) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL232590 | 0.90 | MMP9 (0.70) | MMP9MMP2ITGB3ITGA2BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307505-B2 | Wound dressings for the controlled release of therapeutic agents | KCI USA, INC. (US) | 2019-06-04 | — | — | US | claimed |
| US-20170333592-A1 | Wound Dressings For The Controlled Release Of Therapeutic Agents | SYSTAGENIX WOUND MANAGEMENT, LIMITED (GB) | 2017-11-23 | — | — | US | claimed |
| US-9687581-B2 | Wound dressings for the controlled release of therapeutic agents | KCI USA, INC. (US) | 2017-06-27 | — | — | US | claimed |
| CN-105044335-B | Immunochromatographic test strip for rapid detection of ancylostomiasis infection and preparation method thereof | 中国疾病预防控制中心寄生虫病预防控制所 | 2017-01-25 | — | — | CN | claimed |
| CN-105044335-A | Immunochromatographic test strip for rapid detection of ancylostomiasis infection and preparation method thereof | NAT INST OF PARASITIC DISEASES CHINESE CT FOR DISEASE CONTROL AND PREVENTION | 2015-11-11 | — | — | CN | claimed |
| US-20150098985-A1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC | KCI USA, INC. | 2015-04-09 | — | — | US | claimed |
| EP-1687039-B1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | ETHICON INC (US) | 2009-01-28 | — | — | EP | claimed |
| US-20080171691-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE | 2008-07-17 | — | — | US | claimed |
| EP-0720657-B1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | 3M INNOVATIVE PROPERTIES CO (US) | 2007-08-15 | — | — | EP | claimed |
| US-20070148214-A1 | Wound dressing for the controlled release of therapeutic agents | KCI USA, INC. | 2007-06-28 | — | — | US | claimed |
| EP-1687039-A1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | ETHICON, INC. (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050137121-A1 | Inhibiting or abolishing the protein cleaving action of plasmin, and inhibiting or abolishing the protein cleaving action of a murine metalloprotease. | LUND LEIF R (DK) | 2005-06-23 | — | — | US | claimed |
| WO-2005051441-A1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | ETHICON, INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-0942746-B1 | INHIBITION OF INVASIVE REMODELLING | FONDEN TIL FREMME AF EKSPERIME (DK) | 2005-03-16 | — | — | EP | claimed |
| US-20020099004-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE (DK) | 2002-07-25 | — | — | US | claimed |
| US-6180402-B1 | REDUCING SIDE EFFECTS OR ENHANCING SELECTIVITY OF THERAPY BY CONTACTING LIVING CELLS WITH PHOTOSENSITIZING AGENT AND AT LEAST ONE CYSTEINE OR SERINE PROTEASE INHIBITOR | QLT INC. (CA) | 2001-01-30 | — | — | US | claimed |
| US-6121421-A | SIMPLE, EFFICIENT TWO STEP EXTRACTION PROCESS; MIXING CRUDE PREPARATION WITH BUFFER IN WHICH BETA-CASEIN IS INSOLUBLE, PELLETING BETA-CASEIN BY CENTRIFUGING, SUSPENDING PELLET IN BUFFER AND SOLUBILIZER, CENTRIFUGING, SUPERNATANT HAS CASEIN | ABBOTT LABORATORIES (US) | 2000-09-19 | — | — | US | claimed |
| WO-1998022098-A2 | CPP32 INHIBITORS FOR REGULATING APOPTOSIS | QLT PHOTOTHERAPEUTICS, INC. (CA) | 1998-05-28 | — | — | WO | claimed |
| US-4677069-A | Clam derived proteinases | CORNELL RESEARCH FOUNDATION, INC. (US) | 1987-06-30 | — | — | US | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4000905-B1 | PUNCTURE SEALANT | SUMITOMO RUBBER IND (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2024103215-A1 | PHARMACEUTICAL COMBINATION FOR TREATING FATTY LIVER DISEASE AND USE THEREOF | 泽生生技股份有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11732113-B2 | Puncture sealant | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023102381-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4181928-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | Hoth Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4135660-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-4000905-A1 | PUNCTURE SEALANT | Sumitomo Rubber Industries, Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20220153965-A1 | PUNCTURE SEALANT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| WO-2021211808-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210223258-A9 | Method For Protein Kinase Activity Ranking | KINOMICA LIMITED (GB) | 2021-07-22 | — | — | US | disclosed |
| EP-3829572-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS | Vyne Therapeutics Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-11000535-B2 | Anticancer composition and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-05-11 | — | — | US | disclosed |
| US-10870885-B2 | Dendritic cell response gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3627153-B1 | A METHOD OF ASSESSING PROTEIN MODIFICATION STATUS AND IDENTIFYING BIOMARKERS LINKED TO CELL SIGNALING PATHWAYS | UNIV LONDON QUEEN MARY (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3377905-B1 | METHOD FOR PROTEIN KINASE ACTIVITY RANKING | UNIV LONDON QUEEN MARY (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20200249239-A1 | Method For Protein Kinase Activity Ranking | UNIV LONDON QUEEN MARY (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200221753-A1 | TEXTURED INGESTIBLE PRODUCTS | EETBE INC (US) | 2020-07-16 | — | — | US | disclosed |
| EP-2224000-B1 | ANTIBODY AND USE THEREOF | TAO HEALTH LIFE PHARMA CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3627153-A1 | A METHOD OF ASSESSING PROTEIN MODIFICATION STATUS AND IDENTIFYING BIOMARKERS LINKED TO CELL SIGNALING PATHWAYS | Queen Mary University of London (GB) | 2020-03-25 | — | — | EP | disclosed |
| WO-2020023898-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS | MENLO THERAPEUTICS INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-3304075-B1 | A METHOD OF ASSESSING PROTEIN MODIFICATION STATUS AND IDENTIFYING BIOMARKERS LINKED TO CELL SIGNALING PATHWAYS | UNIV LONDON QUEEN MARY (GB) | 2019-08-21 | — | — | EP | disclosed |
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | MENLO THERAPEUTICS INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-10307505-B2 | Wound dressings for the controlled release of therapeutic agents | KCI USA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3478283-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | Menlo Therapeutics Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3377905-A1 | METHOD FOR PROTEIN KINASE ACTIVITY RANKING | Queen Mary University of London (GB) | 2018-09-26 | — | — | EP | disclosed |
| US-20180235931-A1 | USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES | MENLO THERAPEUTICS INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180214469-A1 | ANTICANCER COMPOSITION AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| US-20180217129-A1 | A Method Of Assessing Protein Modification Status And Identifying Biomarkers Linked To Cell Signaling Pathways | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2018-08-02 | — | — | US | disclosed |
| WO-2018136554-A1 | USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES | MENLO THERAPEUTICS INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9993425-B2 | Compositions for intranasal delivery of human insulin and uses thereof | MARINA BIOTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-3304075-A1 | A METHOD OF ASSESSING PROTEIN MODIFICATION STATUS AND IDENTIFYING BIOMARKERS LINKED TO CELL SIGNALING PATHWAYS | Queen Mary University of London (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20180000930-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2018005695-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | MENLO THERAPEUTICS INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9840731-B2 | Preservation of biological materials in non-aqueous fluid media | GENTEGRA, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170333592-A1 | Wound Dressings For The Controlled Release Of Therapeutic Agents | SYSTAGENIX WOUND MANAGEMENT, LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-9782464-B2 | Methods and compositions for inhibiting diseases of the central nervous system | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170196253-A1 | TEXTURED INGESTIBLE PRODUCTS | EETBE, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170196806-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2017-07-13 | — | — | US | disclosed |
| US-9687581-B2 | Wound dressings for the controlled release of therapeutic agents | KCI USA, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| CN-106714544-A | Textured ingestible products | 埃特比公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-105044335-B | Immunochromatographic test strip for rapid detection of ancylostomiasis infection and preparation method thereof | 中国疾病预防控制中心寄生虫病预防控制所 | 2017-01-25 | — | — | CN | disclosed |
| US-9549895-B2 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016193745-A1 | A METHOD OF ASSESSING PROTEIN MODIFICATION STATUS AND IDENTIFYING BIOMARKERS LINKED TO CELL SIGNALING PATHWAYS | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2016-12-08 | — | — | WO | disclosed |
| US-20160184417-A1 | Methods and Compositions for Inhibiting Diseases of the Central Nervous System | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2016-06-30 | — | — | US | disclosed |
| US-20160144024-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2016-05-26 | — | — | US | disclosed |
| US-9259465-B2 | Methods and compositions for inhibiting diseases of the central nervous system | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2971116-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150368719-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9212387-B2 | Method for detection of genes targeted by microRNA | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2015-12-15 | — | — | US | disclosed |
| CN-105044335-A | Immunochromatographic test strip for rapid detection of ancylostomiasis infection and preparation method thereof | NAT INST OF PARASITIC DISEASES CHINESE CT FOR DISEASE CONTROL AND PREVENTION | 2015-11-11 | — | — | CN | disclosed |
| US-20150297619-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE MUCOSAL BARRIER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-10-22 | — | — | US | disclosed |
| US-20150267245-A1 | PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA | GENTEGRA, LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150098985-A1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC | KCI USA, INC. | 2015-04-09 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2014197090-A2 | PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA | GENTEGRA, LLC (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2584046-B1 | METHOD FOR DETECTION OF GENES TARGETED BY MICRORNA | UNIV OKAYAMA NAT UNIV CORP (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-8858987-B2 | Wound dressing for the controlled release of therapeutic agents | SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2780029-A1 | ORAL LEPTIN FORMULATIONS AND USES THEREOF | Université de Montréal (CA) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014145631-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014055936-A1 | PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA | INTEGENX INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20140004148-A1 | Methods and Compositions for Inhibiting Diseases of the Central Nervous System | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-01-02 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| US-20130224110-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | CORNELL UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217050-A1 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING-SOLUBLE GPVI | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2616538-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | Cornell University (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8491890-B2 | Methods and compositions for inhibiting diseases of the central nervous system | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2615458-A1 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING BLOOD-SOLUBLE GPVI | Mochida Pharmaceutical Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2013071396-A1 | ORAL LEPTIN FORMULATIONS AND USES THEREOF | Université de Montréal (CA) | 2013-05-23 | — | — | WO | disclosed |
| US-8445649-B2 | Antibody and use thereof | TAO HEALTH LIFE PHARMA CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| EP-2584046-A1 | KIT FOR DETECTION OF GENES TARGETED BY MICRORNA, AND METHOD FOR DETECTION OF GENES TARGETED BY MICRORNA | National University Corporation Okayama University (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089866-A1 | Kit For Detection of Genes Targeted by MicroRNA, and Method For Detection of Genes Targeted by MicroRNA | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2013-04-11 | — | — | US | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-8168188-B1 | Antibody and utilization of the same | KYOTO UNIVERSITY (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20120094903-A1 | COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF | MARINA BIOTECH INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037457-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | CORNELL UNIVERSITY (US) | 2012-03-22 | — | — | WO | disclosed |
| CN-101340893-B | Intranasal administration of rapid acting insulin | NASTECH PHARM CO | 2012-03-21 | — | — | CN | disclosed |
| US-20110159004-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2011-06-30 | — | — | US | disclosed |
| US-7863245-B2 | Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100297662-A1 | ANTIBODY AND USE THEREOF | FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE (JP) | 2010-11-25 | — | — | US | disclosed |
| US-7811832-B2 | Methods for preserving the viability of photoreceptor cells by anti-FAS-ligand/anti-FAS-receptor antibodies | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1696960-B1 | INTRANASAL ADMINISTRATION OF GLUCOSE-REGULATING PEPTIDES | AMYLIN PHARMACEUTICALS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-2224000-A1 | ANTIBODY AND USE THEREOF | Kyoto University (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20100210506-A1 | INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN | MDRNA, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1951198-B1 | INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN | MDRNA INC (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100074882-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-25 | — | — | US | disclosed |
| US-20100028320-A1 | Methods and Compositions for Inhibiting Diseases of the Central Nervous System | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2010-02-04 | — | — | US | disclosed |
| US-20090325860-A1 | COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2009-12-31 | — | — | US | disclosed |
| CN-100569281-C | Preparation and use of composition for treating and preventing necrosis | ILANA NATHAN (IL) | 2009-12-16 | — | — | CN | disclosed |
| US-7592330-B2 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090118158-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2009-05-07 | — | — | US | disclosed |
| EP-2046284-A1 | COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF | Nastech Pharmaceutical Company Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20090054326-A1 | FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1687039-B1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | ETHICON INC (US) | 2009-01-28 | — | — | EP | disclosed |
| CN-101340893-A | Intranasal administration of rapid acting insulin | NASTECH PHARM CO (US) | 2009-01-07 | — | — | CN | disclosed |
| US-20080318837-A1 | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318861-A1 | Mucosal Delivery of Stabilized Formulations of Exendin | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080234200-A1 | Saline formulation of a glucose-regulating peptide (amylin, synthtic hormone pramlintide, glucon like peptide-1, extendins), water, sodium chloride and a buffering agent; identical ph and osmolarity for both transmucosal glucose regulating peptide and saline water; antidiabetic, antiobesity agent | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1965828-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | Nastech Pharmaceutical Company Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| CN-101262888-A | Formulations for enhanced mucosal delivery of PYY | NASTECH PHARM CO (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1959987-A2 | MUCOSAL DELIVERY OF STABILIZED FORMULATIONS OF EXENDIN | Nastech Pharmaceutical Company Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1951198-A2 | INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN | Nastech Pharmaceutical Company Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080171691-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE | 2008-07-17 | — | — | US | disclosed |
| US-20080113011-A1 | Compositions and methods for enhanced mucosal delivery of interferon beta | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1664719-A4 | METHODS FOR SUBSTANTIALLY SIMULTANEOUS EVALUATION OF A SAMPLE CONTAINING A CELLULAR TARGET AND A SOLUBLE ANALYTE | BECKMAN COULTER INC (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1907008-A2 | FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY | Nastech Pharmaceutical Company Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1539220-A4 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA | NASTECH PHARM CO (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008016729-A1 | COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20080004218-A1 | METHODS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES FOR TREATING AND PREVENTING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007146448-A1 | PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287756-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-12-13 | — | — | US | disclosed |
| US-20070275893-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-11-29 | — | — | US | disclosed |
| CN-101080421-A | Antibody and use thereof | MITSUBISHI CHEM CORP (JP) | 2007-11-28 | — | — | CN | disclosed |
| US-20070232537-A1 | INTRANASAL PYY FORMULATIONS WITH IMPROVED TRANSMUCOSAL PHARMACOKINETICS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070213270-A1 | PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| EP-0720657-B1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | 3M INNOVATIVE PROPERTIES CO (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070185035-A1 | ENHANCED MUCOSAL ADMINISTRATION OF NEUROPROTECTIVE PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070148214-A1 | Wound dressing for the controlled release of therapeutic agents | KCI USA, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007067964-A2 | MUCOSAL DELIVERY OF STABILIZED FORMULATIONS OF EXENDIN | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007065156-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129299-A1 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007061434-A2 | A PHARMACEUTICAL FORMULATION OF GLP-1 AND ITS USE FOR TREATING A METABOLIC SYNDROME | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1787998-A1 | ANTIBODY AND UTILIZATION OF THE SAME | Mitsubishi Chemical Corporation (JP) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007047948-A2 | INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186692-B2 | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2007019427-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032427-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-02-08 | — | — | US | disclosed |
| US-7166575-B2 | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2007008778-A2 | FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1715885-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006007412-A9 | PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS | NASTECH PHARM CO (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060210614-A1 | Mucosal delivery-enhancing agent selected from a solubilization agent; a charge-modifying agent; a pH control agent; a degradative enzyme inhibitor; a mucolytic/mucus clearing agent; increased bioavailability of exendins peptide when administered intranasally to a mammal; antidiabetic/antiobesity agent | NASTECH PHARMACEUTICAL COMPANY INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1696960-A1 | INTRANASAL ADMINISTRATION OF GLUCOSE-REGULATING PEPTIDES | Nastech Pharmaceutical Company Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1687039-A1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | ETHICON, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1664719-A2 | METHODS FOR SUBSTANTIALLY SIMULTANEOUS EVALUATION OF A SAMPLE CONTAINING A CELLULAR TARGET AND A SOLUBLE ANALYTE | Beckman Coulter, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060074025-A1 | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability | NASTECH PHARMACEUTICAL COMPANY INC. | 2006-04-06 | — | — | US | disclosed |
| US-20060069021-A1 | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs | NASTECH PHARMACEUTICAL COMPANY INC. | 2006-03-30 | — | — | US | disclosed |
| US-20060024744-A1 | Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte | BECKMAN COULTER, INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006007412-A2 | PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005105133-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1581245-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005080433-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005075015-A1 | TREATMENT DEVICE FOR WOUND THERAPY | ETHICON, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| CN-1655809-A | Compositions and methods for treating and preventing necrosis | ILANA NATHAN (IL) | 2005-08-17 | — | — | CN | disclosed |
| WO-2005065714-A1 | INTRANASAL ADMINISTRATION OF GLUCOSE-REGULATING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143303-A1 | Intranasal administration of glucose-regulating peptides | NASTECH PHARMACEUTICAL COMPANY INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050137121-A1 | Inhibiting or abolishing the protein cleaving action of plasmin, and inhibiting or abolishing the protein cleaving action of a murine metalloprotease. | LUND LEIF R (DK) | 2005-06-23 | — | — | US | disclosed |
| US-20050129684-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2005-06-16 | — | — | US | disclosed |
| EP-1539220-A2 | COMPOSITIONS AND METHOD FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA | Nastech Pharmaceutical Company Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539208-A2 | COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | Nastech Pharmaceutical Company Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051441-A1 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | ETHICON, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005036123-A2 | METHODS FOR SUBSTANTIALLY SIMULTANEOUS EVALUATION OF A SAMPLE CONTAINING A CELLULAR TARGET AND A SOLUBLE ANALYTE | BECKMAN COULTER, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050069958-A1 | Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte | BECKMAN COULTER, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-0942746-B1 | INHIBITION OF INVASIVE REMODELLING | FONDEN TIL FREMME AF EKSPERIME (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-20050002927-A1 | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040214772-A1 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040209807-A1 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1450764-A2 | DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040157777-A1 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. | 2004-08-12 | — | — | US | disclosed |
| EP-0720657-A4 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | 3M INNOVATIVE PROPERTIES CO (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004056314-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040115135-A1 | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity | MARINA BIOTECH, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040077540-A1 | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds | NASTECH PHARMACEUTICAL COMPANY INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040037809-A1 | Compositions and methods for enhanced mucosal delivery of interferon beta | NASTECH PHARMACEUTICAL COMPANY INC. | 2004-02-26 | — | — | US | disclosed |
| US-20040028613-A1 | Dopamine agonist formulations for enhanced central nervous system delivery | NASTECH PHARMACEUTICAL COMPANY INC | 2004-02-12 | — | — | US | disclosed |
| WO-2004002404-A2 | COMPOSITIONS AND METHOD FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004003145-A2 | COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003000018-A2 | DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020192754-A1 | Method for producing active serine proteases and inactive variants | MAX-PLANCK-GESELLSCHAFT E.V. (DE) | 2002-12-19 | — | — | US | disclosed |
| EP-0850244-B1 | TOXOPLASMA GONDII GLYCOCONJUGATES | ORGANON TEKNIKA BV (NL) | 2002-07-31 | — | — | EP | disclosed |
| US-20020099004-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE (DK) | 2002-07-25 | — | — | US | disclosed |
| CN-1352682-A | Cysteine protease and inhibitors for the prevention and treatment of neurocysticercosis | UNIV GEORGIA RESAERCH FOUNDATI (US) | 2002-06-05 | — | — | CN | disclosed |
| US-20020058288-A1 | Compound for use in the detection and prevention of parasitic infection of humans | AKZO NOBEL N.V. (NL) | 2002-05-16 | — | — | US | disclosed |
| US-6180402-B1 | REDUCING SIDE EFFECTS OR ENHANCING SELECTIVITY OF THERAPY BY CONTACTING LIVING CELLS WITH PHOTOSENSITIZING AGENT AND AT LEAST ONE CYSTEINE OR SERINE PROTEASE INHIBITOR | QLT INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| US-6121421-A | SIMPLE, EFFICIENT TWO STEP EXTRACTION PROCESS; MIXING CRUDE PREPARATION WITH BUFFER IN WHICH BETA-CASEIN IS INSOLUBLE, PELLETING BETA-CASEIN BY CENTRIFUGING, SUSPENDING PELLET IN BUFFER AND SOLUBILIZER, CENTRIFUGING, SUPERNATANT HAS CASEIN | ABBOTT LABORATORIES (US) | 2000-09-19 | — | — | US | disclosed |
| WO-2000011890-A2 | METHODS FOR ISOLATING RECOMBINANT β-CASEIN | ABBOTT LABORATORIES (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5976859-A | COMPOSITIONS FOR CLEANING AND WASHING PURPOSES. | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5863742-A | LYSING CELLS IN SAMPLE WITH NONIONIC DETERGENT TO RELEASE MX PROTEIN, INACTIVATING PROTEASE BY HEATING WITH DENATURING AGENT, REACTING SOLUTION WITH MONOCLONAL ANTIBODY CLONE, DETECTING BINDING OF ANTIBODY TO PROTEIN | CHIRON DIAGNOSTICS CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| US-5849988-A | Rat comprising straight filaments in its brain | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0749493-B1 | INHIBITION OF PROTEASE ACTIVITY OF HUMAN WHOLE BLOOD CELL LYSATES | CIBA CORNING DIAGNOSTICS CORP (US) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998022098-A2 | CPP32 INHIBITORS FOR REGULATING APOPTOSIS | QLT PHOTOTHERAPEUTICS, INC. (CA) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998021319-A1 | DETERGENT-STABLE MICROBIAL PROTEASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5700659-A | GENETIC ENGINEERED GENE FOR GENE EXPRESSION | KABUSHIKI KAISHA TOYOTA CHUO KENKUSHO (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0749493-A1 | INHIBITION OF PROTEASE ACTIVITY OF HUMAN WHOLE BLOOD CELL LYSATES | Ciba Corning Diagnostics Corp. (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0720657-A1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | NORTH AMERICAN SCIENCE ASSOCIATES INCORPORATED (US) | 1996-07-10 | — | — | EP | disclosed |
| US-5496719-A | THERMOSTABILITY, CATALYST FOR DISULFIDE EXCHANGE IN PROTEINS | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5486459-A | Biologically relevant methods for the rapid determination of sterility | MEDICAL COLLEGE OF OHIO (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995035366-A1 | ANIMAL MODEL FOR ALZHEIMER'S DISEASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-12-28 | — | — | WO | disclosed |
| WO-1995024500-A1 | INHIBITION OF PROTEASE ACTIVITY OF HUMAN WHOLE BLOOD CELL LYSATES | CIBA CORNING DIAGNOSTICS CORP. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995008639-A1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | NORTH AMERICAN SCIENCE ASSOCIATES, INC. (US) | 1995-03-30 | — | — | WO | disclosed |
| WO-1994012640-A1 | RECOMBINANT NUCLEIC ACID, POLYPEPTIDE MATERIAL CODED THEREBY AND TRANSMISSION BLOCKING VACCINE BASED THEREON FOR CONTROLLING THE MALARIA PARASITE $i(PLASMODIUM FALCIPARUM ) | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 1994-06-09 | — | — | WO | disclosed |
| US-5310880-A | Chromatography, alkali halide, acid solution | THE GENERAL HOSPITAL CORPORATION (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0554064-A1 | Vaccine against schistosomiasis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992018145-A1 | PURIFICATION OF MÜLLERIAN INHIBITING SUBSTANCE | THE GENERAL HOSPITAL CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0323802-A2 | Monoclonal antibodies against, and cell surface antigen of, lung carcinoma | SANDOZ AG (CH) | 1989-07-12 | — | — | EP | disclosed |
| US-4677069-A | Clam derived proteinases | CORNELL RESEARCH FOUNDATION, INC. (US) | 1987-06-30 | — | — | US | disclosed |
| US-4677069-A | Clam derived proteinases | CORNELL RESEARCH FOUNDATION, INC. (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | MMP9 664/4885MMP2 882/4885ITGB3 1250/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | MMP9 2494/4885MMP2 4687/4885ITGB3 2892/4885 |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | MMP9 279/4885MMP2 255/4885ITGB3 680/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | MMP9 664/4885MMP2 882/4885ITGB3 1250/4885 |
| US-20020058288-A1 | Compound for use in the detection and prevention of parasitic infection of humans | CD4, OGA, GPI | MMP9 3744/4885MMP2 1576/4885ITGB3 261/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | MMP9 2057/4885MMP2 3595/4885ITGB3 3439/4885 |
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | BDKRB2, BDKRB1, PBK | MMP9 2951/4885MMP2 3262/4885ITGB3 2318/4885 |
| US-20180235931-A1 | USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES | OPRK1, TAC3, BRS3 | MMP9 4261/4885MMP2 2923/4885ITGB3 1824/4885 |
| US-20090054326-A1 | FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY | NPY1R, NPY5R, NPY2R | MMP9 2387/4885MMP2 2339/4885ITGB3 4332/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | MMP9 402/4885MMP2 1445/4885ITGB3 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.